Sign in
Taking people in United KingdomPhase 1

Testing CHM-029 pill in adults with relapsed or hard-to-treat acute myeloid leukemia

Tests the new pill CHM-029 in adults with relapsed or hard-to-treat leukemia.

Key facts

Who runs it
Charm Therapeutics
Where
Manchester, Oxford, and Wales, United KingdomSee the 3 sitesAlso in 6 other countries, 18 sites
Registry title
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Status
Recruiting
Phase
Phase 1
People taking part
40 people, planned
Started
28 Sept 2026
Expected to end
Mar 2029
Type of study
Interventional, 2 groups
Treatments tested
  • CHM-029
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose acute myeloid leukemia (AML) came back or did not respond to treatment, and whose leukemia carries an NPM1 mutation, or a KMT2A or NUP98 rearrangement.

Age
18 years and older
Sex
All sexes can join.
Disease stage
Relapsed or refractory acute myeloid leukemia (AML), meaning the leukemia came back or did not respond to treatment.
Earlier treatment
People must have already had treatment with any available standard therapies.
Biomarker or test result
Positive for an NPM1 mutation, or a KMT2A or NUP98 rearrangement.

Main reasons for not taking part

  • White blood cell count higher than 25,000 u/L that cannot be kept lower with hydroxyurea
  • AML only outside the bone marrow (extramedullary only AML)
  • Current complications from a hematopoietic stem cell transplant (HSCT)
  • Active hepatitis or HIV infection
  • Acute promyelocytic leukemia

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • 18 years old and above
  • Relapsed or refractory (R/R) acute myeloid leukemia (AML) and has had treatment with any available standard therapies
  • Positive for NPM1 mutation, or KMT2A or NUP98 rearrangements

Who cannot take part

  • Has current complications related to hematopoietic stem cell transplant (HSCT)
  • Central nervous system involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
  • Other cancers that require treatment
  • Active Hepatitis or HIV infection
  • Moderate hepatic or renal impairment
  • Congestive heart failure NYHA Class 3 or 4
  • White blood cell (WBC) count higher than 25,000 u/L that cannot be maintained below threshold with hydroxyurea treatment
  • Baseline prolongation of QT/QTc interval (≥ 470 ms) or additional risk factors for Torsades de Pointes (TdP)
  • Extramedullary only AML
  • Acute promyelocytic leukemia

Where in United Kingdom

Also in 6 other countries, 18 sites

  • The Christie NHS Foundation TrustManchester, United KingdomContact: Emma Searle, MDTaking people
  • Oxford University Hospitals NHS Foundation TrustOxford, United KingdomContact: Paresh Vyas, ProfessorTaking people
  • Cardiff & Vale University HospitalWales, United KingdomContact: Stephen Knapper, MDTaking people

About the trial

What the trial wants to find out

The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults. The main questions the study aims to answer are:

Read full original descriptionShow less

* What is an appropriate dose of CHM-029? * What side effects may occur with CHM-029? * How does the body process CHM-029?

Researchers will evaluate increasing dose levels of CHM-029 to better understand its safety and how the body responds to treatment.

Participants will visit the study clinic regularly for safety assessments, blood tests, electrocardiograms (ECGs), and bone marrow evaluations to monitor their health and response to treatment.

The 2 groups in the trial

  • CHM-029 Dose EscalationTreatment being tested

    Participants will receive CHM-029 orally. Dose levels will be escalated based on dose limiting toxicities (DLTs) as evaluated by the Safety Review Committee (SRC).

    Treatment: CHM-029

  • CHM-029 BackfillTreatment being tested

    Participants will receive CHM-029 orally at a dose level already evaluated by the Safety Review Committee (SRC).

    Treatment: CHM-029

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029 as Monotherapy in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) With NPM1 Mutations, KMT2A or NUP98 Rearrangements
Plain-language title
Testing CHM-029 pill in adults with relapsed or hard-to-treat acute myeloid leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
6 November 2026